Results 41 to 50 of about 70,680 (286)
Advanced Healthcare Materials, EarlyView.This work presents ARC‐3D, a soft 3D model that recreates how brain support cells, called astrocytes, react to oxidative stress. The system visualizes rapid calcium changes and inflammatory signals, and shows how the drug KDS12025 can protect cells from damage. ARC‐3D offers a simple, reliable way to study early drivers of brain inflammation.
Ju‐Kang Kim +6 more
wiley +1 more source
BMC Veterinary Research, 2023 Background Porcine circovirus 2 (PCV-2) is one of the pathogens that leads to a growing and persistent threat in pigs. Thus, the development of serological detection methods for PCV-2 is of great necessity for clinical diagnosis as well as ...
Yanwei Li +5 more
doaj +1 more source
Transient Expression of Tetrameric Recombinant Human Butyrylcholinesterase in Nicotiana benthamiana. [PDF]
, 2016 To optimize the expression, extraction and purification of plant-derived tetrameric recombinant human butyrylcholinesterase (prBChE), we describe the development and use of plant viral amplicon-based gene expression system; Tobacco Mosaic Virus (TMV) RNA-
Alkanaimsh, Salem +13 more
core +1 more source
Advanced Healthcare Materials, EarlyView.Zinc‐containing bioactive glass (ZnBG) promotes diabetic wound healing by regulating macrophage extracellular traps (METs). Specifically, ZnBG reduces oxidative stress and inhibits the PAD4 and NLRP3/caspase‐1/GSDMD signaling pathways, thereby suppressing MET formation.
RuiYang Sun +11 more
wiley +1 more source
Glucosamine HCl-based solid dispersions to enhance the biopharmaceutical properties of acyclovir [PDF]
, 2019 The objective of the work presented here was to assess the feasibility of using glucosamine HCl as a solid-dispersion (SD) carrier to enhance the biopharmaceutical properties of a BCS class III/IV drug, acyclovir (ACV). The solid-dispersions of acyclovir
Bhagat, Snehal B. +6 more
core +1 more source
Process analytical technology (PAT) for biopharmaceuticals [PDF]
, 2011 Process analytical technology (PAT), the regulatory initiative for building in quality to pharmaceutical manufacturing, has a great potential for improving biopharmaceutical production.
Bruggeman +41 more
core +1 more source
Advanced Materials, EarlyView.A cryoprotectant‐compatible nanoporous platform enables ambient‐stable and scalable delivery of gene editing therapeutics. By combining hierarchical pore architecture with optimized lyophilization chemistry, the system preserves Cas9‐RNP activity post‐freeze‐drying.
Sian Lee +8 more
wiley +1 more source
Study of firm-level strategic alliances drivers; case study Pharmaceutical industry [PDF]
پژوهشهای مدیریت عمومی, 2015 Commercialization is one of the essential element for development in The biotechnology industry. Nowadays Successful Commercialization is critical for surviving in the competitive markets.
doaj +1 more source
A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints [PDF]
, 2015 In an adaptive seamless phase II/III clinical trial interim analysis data are used for treatment selection, enabling resources to be focussed on comparison of more effective treatment(s) with a control.
Friede, Tim +4 more
core +1 more source
Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects
Advanced Materials, EarlyView.Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley +1 more source